April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Central Retinal Vein Occlusions Treated With Enoxaparin
Author Affiliations & Notes
  • H. T. Rahman
    Ophthalmology, Baylor College of Medicine, Houston, Texas
  • P. E. Carvounis
    Ophthalmology, Baylor College of Medicine, Houston, Texas
  • E. R. Holz
    Ophthalmology, Baylor College of Medicine, Houston, Texas
  • Footnotes
    Commercial Relationships  H.T. Rahman, None; P.E. Carvounis, None; E.R. Holz, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5387. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. T. Rahman, P. E. Carvounis, E. R. Holz; Central Retinal Vein Occlusions Treated With Enoxaparin. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5387.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To describe the successful treatment of acute and subacute unilateral central retinal vein occlusions (CRVOs) with weight based enoxaparin (Lovenox, Sanofi-Aventis, Collegeville, PA) subcutaneously every 12 hours.

Methods: : In a retrospective, non-comparative, consecutive case series, four patients with acute or subacute unilateral CRVOs were treated with enoxaparin 1mg/kg subcutaneously every 12 hours for at least 1 month. Main outcome measures included visual acuity, venous caliber, intraretinal hemorrhages, neovascularization, and macular edema by clinical ophthalmoscopy and optical coherence tomography (OCT).

Results: : Baseline visual acuity on initiation of enoxaparin therapy ranged from 20/25 to count fingers vision. After treatment, all 4 patients showed significant improvement in visual acuity ranging from 20/15 to 20/100. Two patients had complete resolution of their macular edema while the remaining two patients had significantly improved macular edema as measured by OCT. All patients had complete resolution or significant improvement of venous caliber and intraretinal hemorrhages. No patients developed neovascularization or adverse bleeding outcomes.

Conclusions: : Subcutaneous, weight based, enoxaparin twice daily may be an effective means to improve visual acuity, improve macular edema, and prevent neovascularization in acute and subacute CRVOs. Further study through a larger clinical trial is warranted.

Keywords: retina • edema 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.